Detailed narrative
Operational Progress & Financial Discipline
CytoSorbents has significantly reshaped its organization over the past year, focusing on cost reduction, manufacturing efficiency, and commercial operations. These efforts resulted in a substantial reduction in operating cash burn to $200,000 (excluding restructuring costs) in Q2 FY26, positioning the company to achieve operating cash flow breakeven in the second half of FY26. Gross margins improved to 73%, reflecting these disciplined execution efforts across the organization.
DrugSorb-ATR Regulatory Pathway
Despite missing the primary endpoint in the STAR-T trial, the FDA has indicated that a new clinical trial is not required for DrugSorb-ATR. Instead, the agency will consider additional mechanistic data from a small experimental study and real-world evidence from European use. Pre-submission meetings are scheduled for later this month to discuss these requirements for both the ticagrelor indication and a parallel de novo submission for DOAC removal, aiming for clarity on the path to U.S. market entry.
HemoDefend-BGA Strategic Value
The company highlighted HemoDefend-BGA as a fourth value driver, a proprietary gravity-driven filter technology designed to create universal plasma and platelets. Developed with over $16 million in non-dilutive government funding, the technology is now complete and undergoing device validation for human clinical studies. CytoSorbents is actively seeking non-dilutive government funding or strategic partnerships for its clinical development, emphasizing that it will not use internal financial resources for this program at the current time.
CytoSorb Business Performance
The core CytoSorb business demonstrated growth driven by a 16% year-over-year increase in distributor network sales and a 9% rise in direct sales outside Germany. However, sales in Germany remained challenged following restructuring and headcount restrictions. To address this, the company plans to selectively hire 3-5 additional sales representatives through early 2027 to improve territory coverage and restore consistent revenue growth in the region.
STAR-T Clinical Data Insights
The published STAR-T study results for DrugSorb-ATR showed a 58% risk reduction in severe bleeding events or blood loss greater than 1 liter, translating to a number needed to treat (NNT) of 6. While the overall composite endpoint did not achieve statistical significance, analysis limited to severe bleeding in the CABG per protocol population demonstrated a statistically significant win ratio of 1.59. The device also reduced blood product transfusions by 50% for moderate bleeding events, suggesting broad efficacy across the bleeding spectrum.